{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:35:24Z","timestamp":1777012524645,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Despite the obvious survival benefit compared to that among waitlist patients, outcomes of positive crossmatch kidney transplantation (KT) are generally inferior to those of human leukocyte antigen (HLA)-compatible KT. This study aimed to compare the outcomes of positive complement-dependent cytotoxicity (CDC) crossmatch (CDC\u2009+\u2009FC+) and positive flow cytometric crossmatch (CDC-FC+) with those of HLA-compatible KT (CDC-FC-) after successful desensitization.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We retrospectively analyzed 330 eligible patients who underwent KTs between June 2011 and August 2017: CDC-FC- (<jats:italic>n<\/jats:italic>\u2009=\u2009274), CDC-FC+ (<jats:italic>n<\/jats:italic>\u2009=\u200939), and CDC\u2009+\u2009FC+ (<jats:italic>n<\/jats:italic>\u2009=\u200917). Desensitization protocol targeting donor-specific antibody (DSA) involved plasmapheresis, intravenous immunoglobulin (IVIG), and rituximab with\/without bortezomib for positive-crossmatch KT.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Death-censored graft survival and patient survival were not different among the three groups. The median estimated glomerular filtration rate was significantly lower in the CDC\u2009+\u2009FC+ group than in the compatible group at 6\u2009months (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and 2\u2009years (<jats:italic>P<\/jats:italic>\u2009=\u20090.020). Biopsy-proven rejection within 1\u2009year of CDC-FC-, CDC-FC+, and CDC\u2009+\u2009FC+ were 15.3, 28.2, and 47.0%, respectively. Urinary tract infections (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), <jats:italic>Pneumocystis jirovecii<\/jats:italic> pneumonia (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and cytomegalovirus viremia (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) were more frequent in CDC-FC+ and CDC\u2009+\u2009FC+ than in CDC-FC-.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study showed that similar graft and patient survival was achieved in CDC-FC+ and CDC\u2009+\u2009FC+ KT compared with CDC-FC- through DSA-targeted desensitization despite the higher incidence of rejection and infection than that in compatible KT.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12882-019-1625-2","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T17:03:31Z","timestamp":1575911011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Transplant outcomes in positive complement-dependent cytotoxicity- versus flow cytometry-crossmatch kidney transplant recipients after successful desensitization: a retrospective study"],"prefix":"10.1186","volume":"20","author":[{"given":"Deok Gie","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juhan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Younhee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myoung Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon Joo","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Seun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beom Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu Ha","family":"Huh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"issue":"10","key":"1625_CR1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1056\/NEJMoa1508380","volume":"374","author":"BJ Orandi","year":"2016","unstructured":"Orandi BJ, Luo X, Massie AB, Garonzik-Wang JM, Lonze BE, Ahmed R, Van Arendonk KJ, Stegall MD, Jordan SC, Oberholzer J, et al. Survival benefit with kidney transplants from HLA-incompatible live donors. N Engl J Med. 2016;374(10):940\u201350.","journal-title":"N Engl J Med"},{"issue":"7","key":"1625_CR2","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/ajt.12786","volume":"14","author":"BJ Orandi","year":"2014","unstructured":"Orandi BJ, Garonzik-Wang JM, Massie AB, Zachary AA, Montgomery JR, Van Arendonk KJ, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, et al. Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2014;14(7):1573\u201380.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"issue":"1","key":"1625_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1600-6143.2012.04291.x","volume":"13","author":"A Bentall","year":"2013","unstructured":"Bentall A, Cornell LD, Gloor JM, Park WD, Gandhi MJ, Winters JL, Chedid MF, Dean PG, Stegall MD. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2013;13(1):76\u201385.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"issue":"3","key":"1625_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/j.1600-6143.2008.02524.x","volume":"9","author":"A Haririan","year":"2009","unstructured":"Haririan A, Nogueira J, Kukuruga D, Schweitzer E, Hess J, Gurk-Turner C, Jacobs S, Drachenberg C, Bartlett S, Cooper M. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2009;9(3):536\u201342.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"issue":"8","key":"1625_CR5","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.2215\/CJN.02940311","volume":"6","author":"JM Garonzik Wang","year":"2011","unstructured":"Garonzik Wang JM, Montgomery RA, Kucirka LM, Berger JC, Warren DS, Segev DL. Incompatible live-donor kidney transplantation in the United States: results of a national survey. Clin J Am Soc Nephrol. 2011;6(8):2041\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"1625_CR6","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1681\/ASN.2009101065","volume":"21","author":"C Lefaucheur","year":"2010","unstructured":"Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, Gautreau C, Charron D, Glotz D, Suberbielle-Boissel C. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21(8):1398\u2013406.","journal-title":"J Am Soc Nephrol"},{"issue":"13","key":"1625_CR7","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","volume":"369","author":"A Loupy","year":"2013","unstructured":"Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Fremeaux-Bacchi V, Mejean A, Desgrandchamps F, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369(13):1215\u201326.","journal-title":"N Engl J Med"},{"issue":"10","key":"1625_CR8","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1097\/TP.0000000000001619","volume":"101","author":"CA Schinstock","year":"2017","unstructured":"Schinstock CA, Gandhi M, Cheungpasitporn W, Mitema D, Prieto M, Dean P, Cornell L, Cosio F, Stegall M. Kidney transplant with low levels of DSA or low positive B-flow Crossmatch: an underappreciated option for highly sensitized transplant candidates. Transplantation. 2017;101(10):2429\u201339.","journal-title":"Transplantation"},{"issue":"10","key":"1625_CR9","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1097\/TP.0000000000001650","volume":"101","author":"L Amrouche","year":"2017","unstructured":"Amrouche L, Aubert O, Suberbielle C, Rabant M, Van Huyen JD, Martinez F, Sberro-Soussan R, Scemla A, Tinel C, Snanoudj R, et al. Long-term outcomes of kidney transplantation in patients with high levels of preformed DSA: the Necker high-risk transplant program. Transplantation. 2017;101(10):2440\u20138.","journal-title":"Transplantation"},{"issue":"1","key":"1625_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1600-6143.2009.02927.x","volume":"10","author":"JM Cecka","year":"2010","unstructured":"Cecka JM. Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2010;10(1):26\u20139.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"issue":"6","key":"1625_CR11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1097\/TP.0b013e3181856f98","volume":"86","author":"NL Reinsmoen","year":"2008","unstructured":"Reinsmoen NL, Lai CH, Vo A, Cao K, Ong G, Naim M, Wang Q, Jordan SC. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation. 2008;86(6):820\u20135.","journal-title":"Transplantation"},{"issue":"4","key":"1625_CR12","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/j.1600-6143.2006.01721.x","volume":"7","author":"K Mizutani","year":"2007","unstructured":"Mizutani K, Terasaki P, Hamdani E, Esquenazi V, Rosen A, Miller J, Ozawa M. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2007;7(4):1027\u201331.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"issue":"3","key":"1625_CR13","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1600-6143.2009.02985.x","volume":"10","author":"JM Gloor","year":"2010","unstructured":"Gloor JM, Winters JL, Cornell LD, Fix LA, DeGoey SR, Knauer RM, Cosio FG, Gandhi MJ, Kremers W, Stegall MD. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2010;10(3):582\u20139.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"issue":"9","key":"1625_CR14","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/tri.13269","volume":"31","author":"Daigo Okada","year":"2018","unstructured":"Okada D, Okumi M, Kakuta Y, Unagami K, Iizuka J, Takagi T, Ishida H, Tanabe K. Outcome of the risk-stratified desensitization protocol in donorspecific antibody-positive living kidney transplant recipients: a retrospective study. Transpl Int. 2018;31(9):1008\u201317","journal-title":"Transplant International"},{"issue":"11","key":"1625_CR15","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/ndt\/gfy349","volume":"34","author":"Jesmar Buttigieg","year":"2018","unstructured":"Buttigieg J, Ali H, Sharma A, Halawa A. Positive Luminex and negative flow cytometry in kidney transplantation: a systematic review and metaanalysis. Nephrol Dial Transplant. 2018;34(11):1950\u201360.","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"1625_CR16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1600-6143.2008.02159.x","volume":"8","author":"K Solez","year":"2008","unstructured":"Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2008;8(4):753\u201360.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"issue":"9","key":"1625_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1625_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","volume":"96","author":"CN Kotton","year":"2013","unstructured":"Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A, Transplantation Society International CMVCG. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333\u201360.","journal-title":"Transplantation"},{"issue":"7","key":"1625_CR19","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1097\/TXD.0000000000000695","volume":"3","author":"L Pankhurst","year":"2017","unstructured":"Pankhurst L, Hudson A, Mumford L, Willicombe M, Galliford J, Shaw O, Thuraisingham R, Puliatti C, Talbot D, Griffin S, et al. The UK National Registry of ABO and HLA antibody incompatible renal transplantation: Pretransplant factors associated with outcome in 879 transplants. Transplant Direct. 2017;3(7):e181.","journal-title":"Transplant Direct"},{"issue":"4","key":"1625_CR20","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2215\/CJN.08140910","volume":"6","author":"K Marfo","year":"2011","unstructured":"Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin J Am Soc Nephrol. 2011;6(4):922\u201336.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1625_CR21","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.kint.2018.03.015","volume":"94","author":"D Viglietti","year":"2018","unstructured":"Viglietti D, Bouatou Y, Kheav VD, Aubert O, Suberbielle-Boissel C, Glotz D, Legendre C, Taupin JL, Zeevi A, Loupy A, et al. Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. Kidney Int. 2018;94(4):773\u201387.","journal-title":"Kidney Int"},{"issue":"4","key":"1625_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/tri.12873","volume":"30","author":"J Malheiro","year":"2017","unstructured":"Malheiro J, Tafulo S, Dias L, Martins S, Fonseca I, Beirao I, Castro-Henriques A, Cabrita A. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation. Transpl Int. 2017;30(4):347\u201359.","journal-title":"Transpl Int"},{"key":"1625_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.trim.2017.01.001","volume":"41","author":"D Juhl","year":"2017","unstructured":"Juhl D, Marget M, Hallensleben M, Gorg S, Ziemann M. Assignment of C1q-binding HLA antibodies as unacceptable HLA antigens avoids positive CDC-crossmatches prior to transplantation of deceased donor organs. Transpl Immunol. 2017;41:17\u201321.","journal-title":"Transpl Immunol"},{"issue":"3","key":"1625_CR24","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/ndt\/gfr465","volume":"27","author":"J Waiser","year":"2012","unstructured":"Waiser J, Budde K, Schutz M, Liefeldt L, Rudolph B, Schonemann C, Neumayer HH, Lachmann N. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant. 2012;27(3):1246\u201351.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1625_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/TP.0b013e3181c6ff8d","volume":"89","author":"RC Walsh","year":"2010","unstructured":"Walsh RC, Everly JJ, Brailey P, Rike AH, Arend LJ, Mogilishetty G, Govil A, Roy-Chaudhury P, Alloway RR, Woodle ES. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation. 2010;89(3):277\u201384.","journal-title":"Transplantation"},{"issue":"12","key":"1625_CR26","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","volume":"86","author":"MJ Everly","year":"2008","unstructured":"Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86(12):1754\u201361.","journal-title":"Transplantation"},{"issue":"6","key":"1625_CR27","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/TP.0000000000001330","volume":"101","author":"MA Moreno Gonzales","year":"2017","unstructured":"Moreno Gonzales MA, Gandhi MJ, Schinstock CA, Moore NA, Smith BH, Braaten NY, Stegall MD. 32 doses of Bortezomib for desensitization is not well tolerated and is associated with only modest reductions in anti-HLA antibody. Transplantation. 2017;101(6):1222\u20137.","journal-title":"Transplantation"},{"issue":"1","key":"1625_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/ajt.13050","volume":"15","author":"ES Woodle","year":"2015","unstructured":"Woodle ES, Shields AR, Ejaz NS, Sadaka B, Girnita A, Walsh RC, Alloway RR, Brailey P, Cardi MA, Abu Jawdeh BG, et al. Prospective iterative trial of proteasome inhibitor-based desensitization. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2015;15(1):101\u201318.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"issue":"3","key":"1625_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/TP.0000000000001061","volume":"100","author":"S Parajuli","year":"2016","unstructured":"Parajuli S, Muth BL, Turk JA, Astor BC, Mohammed M, Mandelbrot DA, Djamali A. In kidney transplant recipients with a positive virtual Crossmatch, high PRA was associated with lower incidence of viral infections. Transplantation. 2016;100(3):655\u201361.","journal-title":"Transplantation"},{"issue":"12","key":"1625_CR30","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1097\/01.TP.0000442782.98131.7c","volume":"97","author":"LV Riella","year":"2014","unstructured":"Riella LV, Safa K, Yagan J, Lee B, Azzi J, Najafian N, Abdi R, Milford E, Mah H, Gabardi S, et al. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch. Transplantation. 2014;97(12):1247\u201352.","journal-title":"Transplantation"},{"issue":"3","key":"1625_CR31","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/ajt.14472","volume":"18","author":"BJ Orandi","year":"2018","unstructured":"Orandi BJ, Luo X, King EA, Garonzik-Wang JM, Bae S, Montgomery RA, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, et al. Hospital readmissions following HLA-incompatible live donor kidney transplantation: a multi-center study. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2018;18(3):650\u20138.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1625-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1625-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1625-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:32:25Z","timestamp":1607387545000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1625-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1625"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1625-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"29 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the tenets of the Declaration of Helsinki and the Declaration of Istanbul and was approved by the Institutional Review Board of Severance Hospital, Yonsei University Health System (IRB No.: 4\u20132019-0092) with exemption for the informed consent due to the retrospective feature of this study. All kidneys were obtained by the department of transplantation surgery in Severance hospital and we did not use organs from prisoners.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"456"}}